R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 25.

Journal of comparative effectiveness research2026PMID: 41987656

View on PubMed DOI: 10.57264/cer-2026-0073

Plain Language Summary

This health technology assessment update discusses lessons from the failed EVOKE trials of semaglutide in Alzheimer's disease and reviews how real-world evidence is supporting regulatory decisions for various medications including GLP-1 receptor agonists.

Abstract

In this update, we discuss the use of real-world data in the Haute Autorité de Santé assessment of economic evaluations, review how real-world evidence is supporting regulatory approvals in multiple myeloma, and consider lessons from the failed EVOKE trials of semaglutide in Alzheimer's disease for the broader application of target trial emulation.

Authors

Arora, Paul; Ramagopalan, Sreeram V

Keywords

Alzheimer's diseaseEVOKE trialsGLP-1Haute Autorité de Santéhealth technology assessmentmultiple myelomaneurologyoncologyreal-world datareal-world evidencetarget trial emulation